Strides Pharma Science share price today

Strides Pharma Science Ltd's share price was ₹1,014.20 at the close on 4 November 2026. It has been rising for 179 weeks. That is 0.9% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹796 and ₹1,220, and at that close it sat 51% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Strides Pharma Science Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 10 weeks in a row.

Over the last 11 years the share price moved +103% while the NIFTY 500 moved +251%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: revenue up on a year earlier for 12 quarters in a row (every quarter we can compare), indian funds and insurers (DIIs) raised their stake for 4 quarters in a row and foreign funds (FIIs) cut their stake for 3 quarters in a row.

1. Revenue up on a year earlier for 12 quarters in a row (every quarter we can compare)

   In the September 2026 quarter revenue was ₹1,430 crore, +17.1% on a year earlier.

   Why: Revenue rose because sales outside the US grew fast and became bigger than US sales for the first time.

   Next results: check whether the products already launched start bringing in money in the second half.

   From the earnings call on 30 Oct 2026.

2. Indian funds and insurers (DIIs) raised their stake for 4 quarters in a row

   From 13% to 15.5% of the company by the September 2026 quarter.

3. Foreign funds (FIIs) cut their stake for 3 quarters in a row

   From 29.5% to 28% of the company by the September 2026 quarter.

For July to September 2026 (the quarter ended 30 September 2026), Strides Pharma Science reported revenue of ₹1,430 crore, up 17.1% from ₹1,221 crore a year earlier, and a profit of ₹134 crore, up 1.5% from ₹132 crore.

Strides Pharma Science results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Strides Pharma Science's management discussed these results on a call held on 30 October 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

Strides Pharma Science closed at ₹1,014.20 on 4 November 2026, up 7.0% from ₹948.20 a year earlier (7 November 2025) and up 300.7% over five years. Its highest weekly close since March 2016 was ₹1,219.80 on 18 September 2026.

Strides Pharma Science share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

564 weekly closes from 11 March 2016 to 4 November 2026.

4 Nov 2026: Strides Pharma Science closed at ₹1,014.20, down 5.1% on the week and down 6.5% on the month. 30 Oct 2026: Strides Pharma Science held its results call for July to September 2026. Management guided: US $375 million now planned beyond FY28 on shortage normalization and margin discipline.

Earlier

• Results for July to September 2026: Revenue up 17.1% and profit up 1.5% on a year earlier.
• 31 Jul 2026: ex-date for a dividend of ₹5 a share.

Strides Pharma Science paid ₹5 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.49% at the ₹1,014.20 close on 4 November 2026. The last was a dividend of ₹5 a share, ex-date 31 July 2026.

Strides Pharma Science dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date.

Yes. Strides Pharma Science Ltd paid out 8% of its profit as dividends in FY26, and it paid a dividend in 10 of its last 13 reported years. 2 of those years show a negative figure because profit itself was negative.

From the NSE corporate-actions record, read 5 November 2026.

On the call for July to September 2026, held on 30 October 2026, Strides Pharma Science's management guided: US $375 million now planned beyond FY28 on shortage normalization and margin discipline.

“We will not compromise on the profitability or quality of our business to chase revenues.”Badree, on the call for July to September 2026

What management guided

• Ex-US above $375 million by FY28 on broad B2C and B2B momentum plus Sandoz scale.
• 4-6 US launches in H2 with already launched products ramping to stronger second half.
• Nasal spray approval expected January to March 2027 and controlled-substance patch launch Q3 with full FY28 benefit.
• Gross margin within 58-60% band sustainable in H2 on cost-program traction and moderation.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for July to September 2026, 30 October 2026.

When Strides Pharma Science reports October to December 2026, these are the 4 checks that show whether the story is still on course. First: Gross margin stays at flagged sustainable level in next print - per alternate sourcing traction and high-cost stock consumed.

Strides Pharma Science is on 2 of our India lists: Momentum stocks and Pharma stocks.

Strides Pharma Science Ltd earned ₹134 Cr of net profit in the Sep 2026 quarter, +1.5% on the same quarter a year earlier. That is the 5th quarter in a row of profit growth. Full-year FY26 profit was ₹575 Cr. Over 10 years profit has grown 19.7% a year on average. That is 9.4% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹132 Cr.

For the full year, FY26 profit was ₹575 Cr (−84.0% on the year before).

Why profit moved: revenue changed +17.1% on a year earlier and the margin moved −1.0 percentage points. Sales did the work, and the margin was about flat.

On average over the last four quarters, profit changed +59.6% and revenue +11.2%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

Strides Pharma Science Ltd reported ₹1,430 Cr of revenue in the Sep 2026 quarter, +17.1% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 5.4% a year on average. The last full year, FY26, came in at ₹4,859 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹5,213 Cr.

FY26 revenue was ₹4,859 Cr, +6.4% on the year before.

Recent pace: the last four quarters grew +11.2% on average, against 5.4% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +11.3%, against +10.5% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +53.6%, against −57.3% a year (accelerating).

Strides Pharma Science Ltd's operating margin was 18.0% in the Sep 2026 quarter, 1.0 percentage points lower than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 13 years it has been between −17.0% and 19.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed −1.3 percentage points on the year while gross margin changed −1.8 points. So the drop came mostly from the gross margin, which means input costs and prices charged.

As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead.

Over the last 3 years, 42% of Strides Pharma Science Ltd's reported profit came in as cash from its operations, a gap worth watching. In FY26 it brought in ₹703 Cr of operating cash against ₹575 Cr of profit. After ₹644 Cr of spending on assets, ₹59.0 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 42% of profit came in as cash: the cash cycle got 29 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page.

What to look at next: less of the profit turns into cash than it should, and the cash cycle is 29 days longer. The next section looks at where the cash is stuck.

Strides Pharma Science Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 157 days in FY26, up from 128 days in FY21. It spent ₹694 Cr on assets over the last 3 years. Customers take 97 days to pay, and stock sits for 305 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹4,859 Cr, each day of that cycle ties up about ₹13.3 Cr, so roughly ₹2,090 Cr is tied up in the business at any time.

FY26: customers took 97 days to pay and stock sat for 305 days, about 10.0 months of sales sitting as stock, for a full cycle of 157 days, longer than FY21's 128.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 305 days. Customers pay about 97 days after that. Suppliers are paid at 244 days. Together that makes the 157-day cycle.

Spending on assets: ₹694 Cr over the last 3 years, against ₹608 Cr of depreciation (the yearly wear and tear on existing assets). So it is building a little beyond replacing what wears out. Work still in progress is ₹447 Cr (FY26): assets paid for that are not earning yet.

In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit.

Strides Pharma Science Ltd's P/E is 16.2×, in the middle of its own history: higher than 50% of past readings. Its usual P/E (the middle reading) is 16.3×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹66.92.

Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks.